Clinical potential of new antiestrogens

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 840-852

  Gradishar, William J ^a   Jordan, V C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; DROLOXIFENE; ESTRADIOL; FULVESTRANT; IDOXIFENE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; RALOXIFENE; TAMOXIFEN; TOREMIFENE;

ADVANCED CANCER; BONE DENSITY; BREAST CANCER; CARCINOGENICITY; GENE TARGETING; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 0031026744     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.840     Document Type: Review

References (138)

1. Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205, 1984
2. Jordan VC: The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole. Breast Cancer Res Treat 11:197-209, 1988
3. Lerner LJ, Jordan VC: Development of antiestrogens and their use in breast cancer. Eighth Cain Memorial Lecture. Cancer Res 50:4177-4189, 1990
4. Jaiyesimi IA, Buzdar AU, Decker DA, et al.: Use of tamoxifen for breast cancer twenty eight years later. J Clin Oncol 13:513-529, 1995
5. Jordan VC (ed): Long-Term Tamoxifen Treatment for Breast Cancer. Madison, WI, University of Wisconsin, 1994
6. Jordan VC: Current view of the use of tamoxifen for the treatment and prevention of breast cancer. Gaddum Memorial Lecture. Br J Pharmacol 110: 507-517, 1993
7. Bilimoria MM, Assikis VJ, Jordan VC: Should adjuvant tamoxifen therapy be stopped at 5 years? Cancer J Sci Am 2:140-150, 1996
8. Morrow M, Jordan VC: Molecular mechanism of resistance to tamoxifen therapy in breast cancer. Arch Surg 128:1187-1191, 1993
9. Tonetti DA, Jordan VC: Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Anticancer Drugs 9:498-507, 1995
10. Jordan VC: What if tamoxifen had been found to produce rat liver tumors in 1973? Ann Oncol 6:29-33,1995
11. Jordan VC, Morrow M: Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 30A: 1714-1721, 1994
12. Assikis VJ, Jordan VC: Gynecological effects of tamoxifen and the association with endometrial cancer. Int J Gynecol Obstet 49:241-257, 1995
13. Assikis VJ, Neven P, Jordan VC, et al. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 32:1464-1476, 1996
14. Jordan VC: Tamoxifen and tumorigencity: A predictable cancer. J Natl Cancer Inst 87:623-626, 1995
15. Jordan VC: Biochemical pharmacology of antiestrogen action. Pharmacol Rev 36:245-276, 1984
16. Jordan VC, Collins MM, Rowsby L, et al.: A monohydroxyiated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305-316, 1977
17. Toko T, Maksuo KI, Shibata J, et al.: Interaction of DP-TAT-59 an active metabolite of new triphenylethylene derivative (TAT- 59) with estrogen receptors. J Steroid Biochem Mol Biol 43:507-514, 1992
18. Jordan VC, Dix CJ, Naylor KE, et al.: Non-steroidal antiestrogens: Their biological effects and potential mechanisms of action. J Toxicol Environ Health 4:364-390, 1978
19. Jordan VC, Lieberman ME, Cormier E, et al.:. Structural requirements for the pharmacological activity of non-steroidal antiestrogens in vitro. Mol Pharmacol 226:272-278, 1984
20. Roos WK, Oeze L, Loser R, et al.: Antiestrogen action of 3-hydroxy-tamoxifen in the human breast cancer cell line MCF-7. J Natl Cancer Inst 71: 55-59, 1983
21. Jones CD, Suarez T, Mossey EH, et al.: Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthenyl] [4-(2-(1-p-pyrrolidinyl ethoxy) - phenyl] methanone methane sulfonic acid. J Med Chem 22:962-966, 1979
22. Rose DP, Fischer AH, Jordan VC: Activity of the antiestrogen trioxifene against N-nitrosomethylurea- induced rat mammary carcinomas. Eur J Cancer Clin Oncol 17:893-898, 1981
23. Manni A, Arafah B, Pearson OH: Changes in endocrine status following antiestrogen administration to premenopausal and postmenopausal women, in Sutherland RL, Jordan VC (eds): Non-steroidal Antioestrogens. Molecular Pharmacology and Antitumour Activity. Syndney, Australia, Academic, 1981, pp 435-452
24. Witte RS, Pruitt B, Tormey DC, et al.: A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinological effects. Cancer 57:34-39, 1986
25. Lee RW, Buzdar AU, Blumenschein GR, et al.: Trioxifene mesylate in the treatment of advanced breast cancer. Cancer 57:40-43, 1986
26. Jones CD, Jevnikar MG, Pike AJ, et al.: Antiestrogens 2, structure activity studies in a series of 3-aroyl-2-(4-hydroxyphenyl)-benzo [b] thiene - 3-yl] [4-[2- (1-piperidinyl) ethoxy] phenyl] methanone hydrochloride (LY156,758) a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem 27:1057-1066, 1984
27. Black LJ, Jones CD, Falcone JF: Antagonism of estrogen action with a new benzothiophene-derived antiestrogen Life Sci 32:1031-1036, 1983
28. Jordan VC, Gosden B: Inhibition of the uterotrophic activity of estrogens and antiestrogens by the short acting antiestrogen LY 117 018. Endocrinology 113:463-468, 1983
29. Jordan VC, Gosden B: Differential antiestrogen actions in the immature rat uterus: A comparision of hydroxylated antiestrogens with high affinity for the estrogen receptor. J Steroid Biochem 19:1249-1258, 1983
30. Lieberman ME, Gorski J, Jordan VC: An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. J Biol Chem 258:4741-4745, 1983
31. Schull M, Huff KK, Lippman ME: Antiestrogenic effects of LY117018 in MCF-7 cells. Endocrinology 113:611-617, 1983
32. Poulin R, Merand Y, Poirier D, et al.: Antiestrogenic properties of keoxifene, trans 4-hydroxy tamoxifen and ICI 164,384, a new steroidal antiestrogen in ZR-75-1 human breast cancer cells. Breast Cancer Res Treat 14: 655-667, 1989
33. Clemens JA, Bennet DR, Black LJ, et al.: Effects of a new antiestrogen keoxifene (LY156758) on growth of carcinogen induced mammary tumors and on LH and prolactin levels. Life Sci 32:2869-2875, 1983
34. Wakeling AE, Valcaccia B: Antioestrogenic and antitumour activities of a series of non-steriodal antioestrogens. J Endocrinol 99:455-464, 1983
35. Gottardis MM, Jordan VC: The antitumor action of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47:4020-4024, 1987
36. Jordan VC, Phelps E, Lindgren JU: Effects of antiestrogens on bone in castrated and intact female rate. Breast Cancer Res Treat 10:31-35, 1987
37. Evans GL, Bryant HU, Magee D, et al.: The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 134:2283-2288, 1994
38. Black LJ, Sato M, Rowley ER, et al.: Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypotrophy in ovariectomized rats. J Clin Invest 93:63-69, 1994
39. Stao M, Kim J, Short LL, et al.: Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized rats. J Pharmacol Exp Ther 272:1251-1259, 1995
40. Lerner LJ, Holthaus JF, Thompson CR: A non-steroidal estrogen antagonist 1-(p-2-diethylaminoethoxyphenyl)-1 -phenyl-2-p-methoxyphenyl-ethanol. Endocrinology 63:295-318, 1958
41. Wakeling AE: A new approach to breast cancer therapy - Total estrogen ablation with pure antiestrogens, in Jordan VC (ed): Long-Term Tamoxifen Treatment for Breast Cancer. Madison, WI, University of Wisconsin, 1994, pp 219-234
42. Gibson MK, Nemmas LA, Beckman WC, et al.: The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129:2000-2010, 1991
43. Davois S, White R, Parker MG, et al.: The antiestrogen ICI 182 780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106:1377-1388, 1993
44. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873, 1991
45. Howell A, DeFriend D, Robertson J, et al.: Response to a specific antioestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet 345:29-30, 1995
46. Kangas L, Nieminen A-L, Blanco G, et al.: A new triphenyl-ethylene compound Fc-1157a. II antitumor effects. Cancer Chemother Pharmacol 17:109-113, 1986
47. Kangas L: Review of the pharmacological properties of toremifene. J Steroid Biochem 36:191-195, 1990
48. DiSalle E, Zaccheo T, Ornati G: Antioestrogenic and antitumour properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem 36:203-206, 1990
49. Robinson SP, Mauel DA, Jordan VC: Antitumor actions of toremifene in the 7, 12 dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. Eur J Cancer 24:1817-1821, 1988
50. Hayes DF, Van Zyl JA, Hacking A, et al.: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastic breast cancer. J Clin Oncol 113:2556-2566, 1995
51. Hard GC, Iatropoulos MJ, Jordan K et al.: Major differences in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl;CD (BR) rats. Cancer Res 53:4534-4541, 1993
52. Hirsimaki P, Hirsimaki Y, Nieminen L, et al.: Tamoxifen induces hepatocellular carcinoma in rat liver: A 1 year study with 2 antiestrogens. Arch Toxicol 67:49-59, 1993
53. Allen KE, Clark ER, Jordan VC: Evidence for the metabolic activation of nonsteroidal antiestrogens: A study of structure activity relationships. Br J Pharmacol 71:87-91, 1980
54. Lieberman ME, Jordan VC, Fritsch M, et al.: Direct and reversible inhibitors of estradiol-stimulated prolactin synthesis by antiestrogens in vitro. J Biol Chem 258:4734-4740, 1983
55. McCague R, LeClercq G, Legros N, et al.: Derivatives of tamoxifen. Dependency of estrogenicity on the 4 substituent. J Med Chem 32:2527-2533, 1989
56. McCague R, Parr IB, Haynes BP: Metabolism of the 4 iodo derivative of tamoxifen by isolated rat hepatocytes. Demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites. Biochem Pharmcol 40:2277-2283, 1990
57. Grenman RL, Laine KM, Klemi PJ, et al.: Effect of the antiestrogen toremifene on growth of the human mammary carcinoma cell line MCF-7. J Cancer Res Clin Oncol 117:223-226, 1991
58. Colletta AA, Wakefield LM, Howell FV, et al.: Antiestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 62:405-409, 1990
59. Huovinen R, Warn A, Collan Y: Mitotic activity, apoptosis and TRPM-2 messenger RNA expression in DMBA-induced rat mammary carcinoma treated with antiestrogen toremifene. Int J Cancer 55:685-691, 1993
60. Robinson SP, Jordan VC: Antiestrogen action of toremifene on hormone-dependent, independent and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 49:1758-1762, 1989
61. Osborne CK, Jarman M, McCague R, et al.: The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 34:89-95, 1994
62. Styles JA, Davis A, Lim CK, et al.: Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450's. Carcinogenesis 15:5-9, 1994
63. Dragan YP, Vaughn J, Jordan VC, et al.: Comparison of tamoxifen and toremifene on liver and kidney tumor promotion in female rats. Carcinogenesis 16: 2733-2741, 1995
64. Antila M, Valavaara R, Kivinen S, et al.: Pharmacokinetics of toremifene. J Steroid Biochem 36:249-252, 1990
65. Kangas L: Biochemical and pharmacological effects of toremifene metabolites. Cancer Chemother Pharmacol 27:8-12, 1990
66. Wiebe VJ, Benz C, Shermano I: Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemother Phamacol 25:247-251, 1990
67. Webster LK, Crinis NA, Stokes KH, et al.: High performance liquid chromatographic method for the determination of toremifene and its major human metabolites. J Chromatogr B Biomed Appl 565:482-487, 1991
68. Berthou F, Dreano Y: High Performance liquid chromatographic analysis of tamoxifen, toremifene and their major human metabolites. J Chromatogr B Biomed Appl 616:117-127, 1993
69. Bishop J, Muray R, Webster L, et al.: Phase I clinical and pharmacokinetics study of high dose toremifene in postmenopausal patients with advanced breast cancer. Cancer Chemother Pharmacol 30:174-178, 1992
70. Kohler PC, Hamm JF, Wiebe VJ, et al.: Phase I study of the tolerance and pharmacokinetics of tormifene in patients with cancer. Breast Cancer Res Treat 16:19-26, 1991
71. Hamm JT, Tormey DC, Kohler PC, et al.: Phase I study of toremifene in patients with advanced cancer. J Clin Oncol 9:2036-2041, 1991
72. Kivinen S, Maenpaa J: Effect of toremifene on clinical hematological and hormonal parameters at different dose levels in healthy postmenopausal volunteers: Phase I study. J Steroid Biochem 36:217-220, 1990
73. Szamel I, Hindy I, Vincze B, et al.: Influence of toremifene on the endocrine regulation in breast cancer patients. Eur J Cancer 30A: 154-158, 1994
74. Homesley HD, Shemano I, Gamms RA, et al.: Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women. Am J Clin Oncol 16:117-122, 1993
75. Maenpaa J, Sonderatram KO, Granroos M, et al.: Effect of toremifene on estrogen primed vaginal mucosa in postmenopausal women. J Steroid Biochem 36:221-223, 1990
76. Tomas E, Kauppila A, Blanco G, et al.: Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 59:261-266, 1995
77. Tominga T, Abe O, Izuo M, et al.: A phase I study of toremifene. Breast Cancer Res Treat 16:27-27, 1990 (suppl)
78. Valavaara R, Pyrhonen S, Heikkinen M, et al.: Toremifene, a new antiestrogenic treatment of advanced breast cancer. Phase II study. Eur J Cancer 24:785-790, 1988
79. Gunderson S: Toremifene, a new antiestrogenic compound in the treatment of advanced breast cancer. Phase II study. Eur J Cancer 24:785-790, 1990
80. Modig H, Borgstrom M, Nilsson I, et al.: Phase II clinical study of toremifene in patients with metastatic breast cancer. J Steroid Biochem 36:235-236, 1990
81. Valavaara R, Pyrhonen S: Low-dose toremifene in the treatment of estrogen-receptor-positive advanced breast cancer in postmenopausal women. Curr Ther Res 46:966-973, 1989
82. Hietanen T, Baltina D, Johansson R et al.: High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer - An ongoing phase-11 multicenter Finnish-Latvian cooperatie study. Breast Cancer Res Treat 16:37-40, 1990 (suppl)
83. Valavaara R: Phase II experience with toremifene in the treatment of ER-positive breast cancer of postmenopausal women. Cancer Invest 8:275-276, 1990
84. Nomura Y, Tominaga T, Abe O: Clinical evaluation of NK 22 (toremifene citrate) in advanced or recurrent breast cancer - A comparative study by a double blind method with tamoxifen [in Japanse]. Gan to Kagaku Ryoho 20:247-258, 1993
85. Konstantinova MM, Gershanovich ML: Results of comparative clinical evaluation of antiestrogens toremifene and tamoxifen in locally advanced and disseminated breast cancer [in Russian]. Vopr Onkol 36:1182-1186, 1990
86. Stenbygaard LE, Herrstedt J, Thomsen JF, et al.: Toremifene and tamoxifen in advanced breast cancer - A double-blind cross-over trial. Breast Cancer Res Treat 25:57-63, 1993
87. Ebbs SR, Roberts J, Baum M: Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer. Preliminary communication. J Steroid Biochem 36:239, 1990 (abstr)
88. Hindy I, Juhos E, Szanto J, et al.: Effect of toremifene in breast cancer patients. Preliminary communication. J Steroid Biochem 36:225-226, 1990
89. Jonsson P-E, Malmberg M, Bergejung L, et al.: Phase II study of high dose toremifene in advanced breast cancer progressing during tamoxifen treatment. Anticancer Res 11:873-876, 1991
90. Asaishi K, Tominaga T, Abe O: Efficacy and safety of high dose NK 622 (toremifene citrate) in tamoxifen failed patients with breast cancer [in Japanese] Gan to Kagaku Ryoho 20:91-99, 1993
91. Vogel CL, Shemano I, Schoenfelder J, et al.: Multicenter phase II efficacy trial of toremifene in tamoxifen refractory patients with advanced breast cancer. J Clin Oncol 11:345-350, 1993
92. Pyrhonen S, Valavaara R, Vuorinen J, et al.: High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. Breast Cancer Res Treat 29:223-228,1994
93. Perry JJ, Berry DA, Weiss RB, et al.: High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer. A phase II trial of the Cancer and Leukemia Group B (CALGB). Breast Cancer Res Treat 36:35-40, 1995
94. Loser R, Seibel K, Eppenberger U: No loss of estrogenic and antiestrogenic activity after demethylation of droloxifene (3-OH tamoxifen). Int J Cancer 36:701-703, 1985
95. Hasman M, Rattel B, Loser R: Preclinical data for droloxifene. Cancer Lett 84:101-116, 1994
96. Loser R, Seibel K, Roos W, et al.: In vivo and in vitro antiestrogenic action of 3-hydroxy-tamoxifen, tamoxifen and 4-hydroxytamoxifen. Eur J Cancer Clin Oncol 21:985-900, 1985
97. Eppenberger U, Wosikowski K, Kung W: Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Am J Clin Oncol 14:s5-s14, 1991 (suppl 2)
98. Ke HZ, Simmons HA, Pine CM, et al.: Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 136:2435-2441, 1995
99. Kawamura I, Mizota T, Kondo N: Antitumor effects of droloxifene, a new antiestrogen drug against 7,12 dimethylbenz (a) anthracene-induced mammary tumor in rats. Jpn J Pharmacol 57:215-224, 1991
100. Winterfeld G, Hauff P, Grolich M, et al.: Investigations of droloxifene and other hormonal manipulations on N-nitrosomethyl-urea-induced rat mammary tumours. J Cancer Res Clin Oncol 119:91-96, 1992
101. Kawamura I, Mizota T, Lacey E, et al.: Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Jpn J Pharmacol 63:27-34, 1993
102. Metzler M, Schiffmann D: Structural requirements for the in vitro transformation of Syrian hamster embryo cells by stilbene estrogens and triphenylethylene-type antiestrogens. Am J Clin Oncol 14:s30-s35, 1991 (suppl 2)
103. Grill HJ, Pollow K: Pharmacokinetics of droloxifene and its metabolites in breast cancer patients. Am J Clin Oncol 14:s21-s29, 1991 (suppl 2)
104. Lein EA, Anker G, Lonning PE, et al.: Determination of droloxifene and two metabolites in serum by high pressure liquid chromatography. Ther Drug Monit 17:259-265, 1995
105. Geisler J, Ekse, D, Hosch S, et al.: Influence of droloxifene (3-hydroxytamoxifen) 40 mg daily on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol 55:193-195, 1995
106. Ahlemann LM, Staab HJ, Loser R, et al.: Inhibition of growth of human cancer by intermittent exposure to the antiestrogen droloxifene. Tumor Diag Ther 9:41-46, 1988
107. Abe O: Japanese early phase II study of droloxifene in the treatment of advanced breast cancer. Am J Clin Oncol 14:540-451, 1991
108. Abe O, Enomote K, Fujiwara K, et al.: Phase I study of FK 435. Jpn J Cancer Clin 36:903-913, 1990
109. Bellmunt J, Sole L: European early phase II dose finding study of droloxifene in advanced breast cancer. Am J Clin Oncol 14:536-539, 1991
110. Haarstad H, Gundersen S, Wist E, et al.: Droloxifene - A new anti-estrogen phase II study in advanced breast cancer. Acta Oncol 31:425-428, 1992
111. Rausching W, Pritchard KI: Droloxifene, a new antiestrogen: Its role in metastatic breast cancer. Breast Cancer Res Treat 31:83-94, 1994
112. Buzdar AU, Kau S, Hortobagyi GN, et al.: Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol 33:313-316, 1994
113. Chander SK, McCague R, Lugmani Y, et al.: Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res 51:5851-5858, 1991
114. White INH, deMatteis F, Davis A, et al.: Genotoxic potential of tamoxifen and analogues in female Fischer 344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13:2197-2203, 1992
115. Robinson SP, Langan-Fahey SM, Johnson DA, et al.: Metabolites, pharmacodynamics and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Met Disp 19:36-43, 1991
116. Carnochan P, Trivedi M, Young H, et al.: Biodistribution and kinetics of pyrrolidino - 4- iodo-tamoxifen: Prospects for pharmacokinetic studies using PET. J Nucl Biol Med 38:96-98, 1994
117. Coombes RC, Haynes BP, Dowsett M, et al.: Idoxifene: Report of a phase I study in patients with metastatic breast cancer. Cancer Res 55:1070-1074, 1995
118. Toko T, Sigimoto Y, Matsuo KI, et al.: TAT-59 a new triphenylethylene derivative with antitumor activity against hormone dependent tumors. Eur J Cancer 26:397-404, 1990
119. Koh JI, Kubota T, Asanuma F, et al.: Antitumor effect of triphenylethylene derivative (TAT-59) against human breast carcinoma xenografts in nude mice. J Surg Oncol 51:254-258, 1992
120. Iino Y, Takai Y, Ando T, et al.: A new triphenylethylene derivative TAT-59: Hormone receptors, insulin-like growth factor 1 and growth supression of hormone dependent MCF-7 tumors in athymic mice. Cancer Chemother Pharmacol 34:372-376, 1994
121. Osborne CK, Coronado EB, Robinson JP: Human breast cancer in athymic nude mice: Cytostatic effects of long-term antiestrogenic activity. Eur J Cancer 232:1189-1196, 1987
122. Gottardis MM, Jordan VC: Development of tamoxifen stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183-5187, 1988
123. Satyaswaroop PG, Zaino RJ, Mortel R: Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 44:4006-4010, 1984
124. Gottardis MM, Robinson SP, Satyaswaroop PG, et al.: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48:812-815, 1988
125. Gottardis MM, Jiang SY, Jeng MH, et al.: Inhibition of tamoxifen stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49:4090-4093, 1989
126. Gottardis MM, Ricchio MD, Satyaswaroop PG, et al.: Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res 50:3189-3192, 1990
127. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al.: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human cancer. J Natl Cancer Inst 87:746-750, 1995
128. Nicholson RI, Walker KJ, Bouzukar N, et al.: Estrogen deprivation in breast cancer. Clinical, experimental and biological aspects. Ann NY Acad Sci 595:316-327, 1990
129. Wakeling AE, Bowler J: Novel antiestrogens without partial agonist activity. J Steroid Biochem 31:645-653, 1988
130. DeFriend DJ, Howell A, Nicholson RI, et al.: Investigation of a pure new antiestrogen (ICI 182,780) in women with primary breast cancer. Cancer Res 54:408-414, 1994
131. Dukes M, Miller D, Wakeling AE, et al.: Antiuterotrophic effect of a pure antioestrogen ICI 182,780: Magnetic resonance imaging of the uterus in ovariectomized monkeys. J Endocrinol 135:239-247, 1992
132. Dukes M, Waterton JC, Wakeling AE: Antiuterotropic effect of the pure antiestrogen ICI 182,780 in adult female monkeys (Macaca Nemestrina) quantitative magnetic resonance imageing. J Endocrinol 138:203-210, 1993
133. Tonetti DA, Jordan VC: The development of targeted antiestrogens to prevent diseases in women. Mol Med Today 2:218-223, 1996
134. Draper MW, Flowers DE, Hester WJ, et al.: Effects of raloxifene (LY 139481 HCL) on biochemical markers of bone and lipid metabolism in healthy postmenopausal women. Proceedings of the Fourth International Symposium on Osteoporosis. Handelstrykkeriet Aalborg ApS, Aalborg, Denmark, 1993, pp 119-121
135. Draper MW, Flowers DE, Meild JA, et al.: Antiestrogenic properties of raloxifene. Pharmacology 50:209-217, 1995
136. Buzdar AU, Marcus C, Holmes F, et al.: Phase II evaluation of LY156758 in metastatic breast cancer. Oncology 45:344-345, 1988
137. Gylling H, Pyrhonen S, Mantyla E, et al.: Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. J Clin Oncol 13:2900-2905, 1995
138. Gallagher A, Chambers TJ, Tobias JH: The estrogen antagonist ICI 182,780 reduces cancellous bone volumes in female rats. Endocrinology 133:2787-2791, 1993